Drugs / T2000
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00655278 | Aug 2007 → Nov 2009 | essential tremor | Sun Pharmaceutical Industries, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00506012 | Aug 2007 → Aug 2011 | myoclonus, familial | Sun Pharmaceutical Industries, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00321087 | Aug 2006 → Jul 2007 | essential tremor | Sun Pharmaceutical Industries, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T2000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00321087 ↗ |
| Known as | 1,3-dimethoxymethyl-5,5-diphenyl-barbituric Acid | “Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric Acid) in Patients With Essential Tremor: An Open-Label Dose...” NCT00655278 ↗ |
| Modality | Small molecule | — CHEMBL4297439 ↗ |